{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:35:28Z","timestamp":1787016928946,"version":"build-2736575974"},"reference-count":36,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:00:00Z","timestamp":1719360000000},"content-version":"unspecified","delay-in-days":25,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,6,3]]},"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Primary sclerosing cholangitis (PSC) is a progressive immune-mediated liver disease, for which no medical therapy has been shown to slow disease progression. However, the horizon for new therapies is encouraging, with several innovative clinical trials in progress. Despite these advancements, there is considerable heterogeneity in the outcomes studied, with lack of consensus as to what outcomes to measure, when to measure and how to measure. Furthermore, there has been a paradigm shift in PSC treatment targets over recent years, moving from biochemistry-based endpoints to histological assessment of liver fibrosis, imaging-based biomarkers and patient-reported outcome measures. The abundance of new interventional trials and evolving endpoints pose opportunities for all stakeholders involved in evaluating novel therapies. To this effect, there is a need to harmonise measures used in clinical trials through the development of a core outcome set (COS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>Synthesis of a PSC-specific COS will be conducted in four stages. Initially, a systematic literature review will be performed to identify outcomes previously used in PSC trials, followed by semistructured qualitative interviews conducted with key stakeholders. The latter may include patients, clinicians, researchers, pharmaceutical industry representatives and healthcare payers and regulatory agencies, to identify additional outcomes of importance. Using the outcomes generated from the literature review and stakeholder interviews, an international two-round Delphi survey will be conducted to prioritise outcomes for inclusion in the COS. Finally, a consensus meeting will be convened to ratify the COS and disseminate findings for application in future PSC trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethical approval has been granted by the East Midlands\u2014Leicester Central Research Ethics Committee (Ref: 24\/EM\/0126) for this study. The COS from this study will be widely disseminated including publication in peer-reviewed journals, international conferences, promotion through patient-support groups and made available on the Core Outcomes Measurement in Effectiveness Trials (COMET) database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>1239.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2023-080143","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T23:05:45Z","timestamp":1719443145000},"page":"e080143","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Protocol for the development of a core outcome set for clinical trials in primary sclerosing cholangitis"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4167-6846","authenticated-orcid":false,"given":"Nasir","family":"Hussain","sequence":"first","affiliation":[{"name":"NIHR Birmingham Biomedical Research Centre, Birmingham, UK"},{"name":"Centre for Liver and Gastrointestinal Research, University of Birmingham Institute of Immunology and Immunotherapy, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Medicine and Community Health Sciences, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gideon","family":"Hirschfield","sequence":"additional","affiliation":[{"name":"Toronto Centre for Liver Disease, Division of Gastroenterology and Hepatology, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Walmsley","sequence":"additional","affiliation":[{"name":"PSC Support, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Hanford","sequence":"additional","affiliation":[{"name":"PSC Support, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette","family":"Vesterhus","sequence":"additional","affiliation":[{"name":"Norwegian PSC Research Centre, Department of Transplantation Medicine, Division of Surgery, Oslo University Hospital, Oslo, Norway"},{"name":"Department of Clinical Science, University of Bergen, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris","family":"Kowdley","sequence":"additional","affiliation":[{"name":"Liver Care Network and Organ Care Research, Swedish Medical Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Bergquist","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyriel","family":"Ponsioen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Academic Medical Centre, Amsterdam University Medical Centres, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Levy","sequence":"additional","affiliation":[{"name":"Miller School of Medicine, University of Miami, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Assis","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Digestive Disease, Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schramm","sequence":"additional","affiliation":[{"name":"First Department of Medicine, Martin Zeitz Centre for Rare Disease and Hamburg Centre of Translational Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"},{"name":"Hamburg Centre of Translational Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Bowlus","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of California Davis, Davis, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1275-6425","authenticated-orcid":false,"given":"Michael","family":"Trauner","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Wien, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9122-8251","authenticated-orcid":false,"given":"Olalekan Lee","family":"Aiyegbusi","sequence":"additional","affiliation":[{"name":"Centre for Patient-Reported Outcomes Research, University of Birmingham, Birmingham, UK"},{"name":"NIHR Birmingham Biomedical Research Centre, University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8603-898X","authenticated-orcid":false,"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology, Western University, London, Ontario, Canada"},{"name":"Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palak J","family":"Trivedi","sequence":"additional","affiliation":[{"name":"NIHR Birmingham Biomedical Research Centre, Birmingham, UK"},{"name":"Centre for Liver and Gastrointestinal Research, University of Birmingham Institute of Immunology and Immunotherapy, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,6,26]]},"reference":[{"key":"2025121510215757000_14.6.e080143.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60096-3"},{"key":"2025121510215757000_14.6.e080143.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.07.022"},{"key":"2025121510215757000_14.6.e080143.3","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.02.038"},{"key":"2025121510215757000_14.6.e080143.4","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1053\/j.gastro.2020.05.049","article-title":"Effects of primary sclerosing cholangitis on risks of cancer and death in people with inflammatory bowel disease, based on sex, race, and age","volume":"159","author":"Trivedi","year":"2020","journal-title":"Gastroenterology"},{"key":"2025121510215757000_14.6.e080143.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.08.039"},{"key":"2025121510215757000_14.6.e080143.6","unstructured":"Anon . Annual report on liver transplantation. NHSBT; 2021\/2022."},{"key":"2025121510215757000_14.6.e080143.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32866-0"},{"key":"2025121510215757000_14.6.e080143.8","doi-asserted-by":"crossref","first-page":"797","DOI":"10.3109\/00365521.2015.1036359","article-title":"Liver transplantation in the Nordic countries - an intention to treat and post-transplant analysis from the Nordic liver transplant registry 1982-2013","volume":"50","author":"Fosby","year":"2015","journal-title":"Scand J Gastroenterol"},{"key":"2025121510215757000_14.6.e080143.9","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(20)31043-6","article-title":"Projection of liver transplant activity per indication in France and United Kingdom","volume":"73","author":"Connolly","year":"2020","journal-title":"J Hepatol"},{"key":"2025121510215757000_14.6.e080143.10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.coph.2021.11.003","article-title":"Emerging drugs for the treatment of primary Sclerosing cholangitis","volume":"62","author":"Abbas","year":"2022","journal-title":"Curr Opin Pharmacol"},{"key":"2025121510215757000_14.6.e080143.11","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/hep.28128","article-title":"Risk stratification in autoimmune cholestatic liver diseases: opportunities for clinicians and trialists","volume":"63","author":"Trivedi","year":"2016","journal-title":"Hepatology"},{"key":"2025121510215757000_14.6.e080143.12","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/hep.28256","article-title":"Surrogate endpoints for clinical trials in primary Sclerosing cholangitis: review and results from an international PSC study group consensus process","volume":"63","author":"Ponsioen","year":"2016","journal-title":"Hepatology"},{"key":"2025121510215757000_14.6.e080143.13","unstructured":"Phase 2a evaluation of safety, tolerability, and pharmacokinetics of PLN-74809 in patients with primary Sclerosing cholangitis (PSC). n.d. Available: https:\/\/ClinicalTrials.gov\/show\/NCT04480840"},{"key":"2025121510215757000_14.6.e080143.14","unstructured":"Safety and tolerability of Cilofexor in participants with primary Sclerosing cholangitis (PSC) and compensated cirrhosis. n.d. Available: https:\/\/ClinicalTrials.gov\/show\/NCT04060147"},{"key":"2025121510215757000_14.6.e080143.15","unstructured":"CM-101 in PSC patients -The SPRING study. n.d. Available: https:\/\/ClinicalTrials.gov\/show\/NCT04595825"},{"key":"2025121510215757000_14.6.e080143.16","unstructured":"norUrsodeoxycholic acid vs placebo in PSC. n.d. Available: https:\/\/ClinicalTrials.gov\/show\/NCT03872921"},{"key":"2025121510215757000_14.6.e080143.17","unstructured":"Efficacy of 24 month of Bezafibrate in primary Sclerosing cholangitis with persistent cholestasis despite Ursodeoxycholic acid therapy. n.d. Available: https:\/\/ClinicalTrials.gov\/show\/NCT04309773"},{"key":"2025121510215757000_14.6.e080143.18","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/hep.29882","article-title":"Design and endpoints for clinical trials in primary Sclerosing cholangitis","volume":"68","author":"Ponsioen","year":"2018","journal-title":"Hepatology"},{"key":"2025121510215757000_14.6.e080143.19","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30237"},{"key":"2025121510215757000_14.6.e080143.20","unstructured":"European Medicines Agency . Reflection Paper on Regulatory Requirements for the Development of Medicinal Products for Chronic Non-Infectious Liver Diseases (PBC, PSC, NASH). EMA, 2018, 2021."},{"key":"2025121510215757000_14.6.e080143.21","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/hep.28963","article-title":"Validation of the prognostic value of histologic scoring systems in primary Sclerosing cholangitis: an international cohort study","volume":"65","author":"de Vries","year":"2017","journal-title":"Hepatology"},{"key":"2025121510215757000_14.6.e080143.22","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000049","article-title":"Development and validation of a primary Sclerosing cholangitis-specific health-related quality of life instrument: CLDQ-PSC","volume":"7","author":"Younossi","year":"2023","journal-title":"Hepatol Commun"},{"key":"2025121510215757000_14.6.e080143.23","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/hep.29664","article-title":"Development and validation of a primary Sclerosing cholangitis-specific patient-reported outcomes instrument: the PSC PRO","volume":"68","author":"Younossi","year":"2018","journal-title":"Hepatology"},{"key":"2025121510215757000_14.6.e080143.24","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1111\/liv.14644","article-title":"The simple cholestatic complaints score is a valid and quick patient-reported outcome measure in primary Sclerosing cholangitis","volume":"40","author":"van Munster","year":"2020","journal-title":"Liver Int"},{"key":"2025121510215757000_14.6.e080143.25","doi-asserted-by":"crossref","DOI":"10.1186\/1745-6215-13-132","article-title":"Developing core outcome sets for clinical trials: issues to consider","volume":"13","author":"Williamson","year":"2012","journal-title":"Trials"},{"key":"2025121510215757000_14.6.e080143.26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002447","article-title":"Core outcome set-standards for development: the COS-STAD recommendations","volume":"14","author":"Kirkham","year":"2017","journal-title":"PLoS Med"},{"key":"2025121510215757000_14.6.e080143.27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002148","article-title":"Core outcome set-standards for reporting: the COS-STAR statement","volume":"13","author":"Kirkham","year":"2016","journal-title":"PLoS Med"},{"key":"2025121510215757000_14.6.e080143.28","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.cgh.2017.08.025","article-title":"Heterogeneity in definitions of endpoints for clinical trials of ulcerative colitis: a systematic review for development of a core outcome set","volume":"16","author":"Ma","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025121510215757000_14.6.e080143.29","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1053\/j.gastro.2022.06.068","article-title":"CORE-IBD: a multidisciplinary International consensus initiative to develop a core outcome set for randomized controlled trials in inflammatory bowel disease","volume":"163","author":"Ma","year":"2022","journal-title":"Gastroenterology"},{"key":"2025121510215757000_14.6.e080143.30","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-016146","article-title":"Development of a core outcome set for clinical trials in inflammatory bowel disease: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey","volume":"7","author":"Ma","year":"2017","journal-title":"BMJ Open"},{"key":"2025121510215757000_14.6.e080143.31","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jaci.2021.07.001","article-title":"Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS)","volume":"149","author":"Ma","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"2025121510215757000_14.6.e080143.32","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-017-1978-4","article-title":"The COMET Handbook: version 1.0","volume":"18","author":"Williamson","year":"2017","journal-title":"Trials"},{"key":"2025121510215757000_14.6.e080143.33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000393","article-title":"Using the Delphi technique to determine which outcomes to measure in clinical trials: recommendations for the future based on a systematic review of existing studies","volume":"8","author":"Sinha","year":"2011","journal-title":"PLoS Med"},{"key":"2025121510215757000_14.6.e080143.34","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2025121510215757000_14.6.e080143.35","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.a288","article-title":"An introduction to reading and appraising qualitative research","volume":"337","author":"Kuper","year":"2008","journal-title":"BMJ"},{"key":"2025121510215757000_14.6.e080143.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.09.012"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2023-080143","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T18:22:07Z","timestamp":1765822927000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2023-080143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":36,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6,26]]},"published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1136\/bmjopen-2023-080143"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2023-080143","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6]]}}}